Bowel cancer “melted away” after immunotherapy, then stayed away
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had…
Read original article on Health & Medicine News -- ScienceDaily →Related news
-
Loneliness may steal nearly 6 years of good health
-
Why most health apps are biased even before their first lines of code are written
-
Most labs testing children for cardiac troponin lack pediatric reference ranges, survey finds
-
What Is the Pyro Method? How Celebrity Trainer Kirsty Godso Builds Functional Strength
-
The circumstances you grow up in are linked to how long you live
-
Radiation exposure linked to pulmonary hypertension after lung cancer treatment
-
A healthy Nordic diet may help you to live longer, but liver benefits remain unclear
-
The medicine of the future could be driven by mechanical cell memory